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Abstract
Objective: This study was conducted to assess the long-term effect of methylphenidate (MPH) or atomoxetine (ATX) on
growth in attention-deficit/hyperactivity disorder (ADHD) drug-naı¨ve children.
Design: The study was an observational, post-marketing, fourth phase study.
Methods: Data on height and weight were collected at baseline and every 6 months up to 24 months.
Results:BothATXandMPH lead to decreased height gain (assessed bymeans of z-scores); the effect was significantly higher
for ATX than for MPH. At any time, height z-score decrease in the ATX group was higher than the corresponding decrease
observed in theMPH group, but the difference was significantly relevant only during the first year of treatment. An increment
of average weight was observed both in patients treated with MPH and in those treated with ATX. However, using Tanner’s
percentile, a subset of patients showed a degree of growth lower than expected. This negative effect was significantly higher
for ATX than for MPH.
Conclusions:We conclude that ADHD drugs show a negative effect on linear growth in children in middle term. Such effect
appears more evident for ATX than for MPH.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is oneof the most common behavioral disorders in children and
adolescents (Skounti et al. 2007). Pharmacological treatment may
reduce ADHD symptom severity (MTA Cooperative Group 1999;
Biederman and Faraone 2005). Methylphenidate (MPH) and other
psychostimulants are recommended as first-choice drugs for
ADHD (Schachter et al 2001). Atomoxetine (ATX), a selective
norepinephrine reuptake inhibitor, is considered as a second
choice (Cheng et al. 2007). Adverse events may occur both with
psychostimulants and ATX. Available evidence suggests that
children and adolescents are at higher risk than adults for adverse
events during treatment with psychotropic drugs (Greenhill et al.
2003).
According to a systematic review (Faraone et al. 2008),*38%
of included studies showed a growth slowdown in children treated
with ADHD drugs. The effect, although attenuated, persisted over
time for 4 years (Mattes and Gittelman 1983). However, discon-
tinuation of treatment with stimulants showed a compensatory
growth spurt (Mattes and Gittelman 1983; Klein et al. 1988; Klein
and Mannuzza 1988).
As for ATX, meta-analytic evidence shows a slight weight de-
crease (*1 kg) in the short term (2–3 months) (Cheng et al. 2007).
Two additional meta-analyses assessed reported the effect of long-
term use of ATX on height and weight. The first showed a decrease
in weight (average 2.5 kg) and in height (average 2.7 cm) after 2
years of treatment with ATX in 6–7-year-old children in relation to
baseline percentiles (Kratochvil et al. 2006). The second meta-
analysis reported a less evident effect on weight and height, 0.87 kg
and 0.44 cm, respectively (Spencer et al. 2005).
The Italian ADHD National Registry was activated in April
2007. It is managed by the Italian National Institute of Health
(Istituto Superiore di Sanita`, ISS) and supervised by a national
panel of experts with the aim of implementing an active pharmaco-
vigilance, and to assess the risk/benefit ratio of ADHD drugs (Panei
et al. 2004). According to Italian regulation, children can receive
pharmacological treatment for ADHD only after registration with
the ADHD National Registry. Care providers choose the treatment
based on their own experience, and on current clinical practice.
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Italian law requires close monitoring of drugs for 2 years after
registration, in order to assess safety in current clinical practice. An
observational post-marketing study of pharmacovigilance is man-
datory for every new drug approved for ADHD.
The objective of this study was to assess the effect on growth
during 2 years of treatment with MPH or ATX in ADHD children
and adolescents enrolled in the Italian ADHD National Registry.
Patients and Methods
Subjects
This observational prospective study included 1758 children and
adolescents (6–18 years of age)withADHD,whowere consecutively
recruited from87 centers accredited for themanagement ofADHD in
Italy between June 2007 and June 2010. All subjects treated with
ADHD drugs were included in this study and were drug naı¨ve.
Participants were either referred by their child neuropsychia-
trists or self-referred to a reference center for a suspicion of ADHD.
ADHD was diagnosed according to American Psychiatric As-
sociation, Diagnostic and Statistical Manual of Mental Disorders,
4th ed. (DSM-IV) (American Psychiatric Association 1994) criteria
for ADHD based on clinical history and confirmed by a structured
interview. Accordingly, to be diagnosed with ADHD, subjects had
to present with a significant functional impairment and symptoms
had to: 1) Be present, at least in part, before the age of 7 years, 2)
persist for at least 6 months, and 3) be present in more than one
setting (e.g., at home, and/or at school, and/or in another setting).
All subjects were screened for other mental disorders, and partic-
ipants with an autism spectrum disorder were excluded, as per
DSM-IV criteria. Subjects with follow-up or compliance problems
were also excluded.
All subjects who accepted the pharmacological treatment signed
an informed consent explaining the aim of the study and the tests to
be performed in order to evaluate the primary parameters (i.e.,
effect on height growth).
The study was approved by the Ethical Committee of the Istituto
Superiore di Sanita`.
Treatments
Two study groups were defined according to the pharmacolog-
ical treatment, and the choice of treatment was based on current
clinical practice by child neuropsychiatrists.
Group A. This group consisted of subjects treated with MPH
plus behavioral treatment. The drug compound was methylpheni-
date chlorhydrate 10mg tablet (Ritalin, Novartis Pharma, Italia).
MPH was administered orally (0.3–0.6mg/kg/dose/day).
A methylphenidate test dose of 0.3mg/kg was administered first.
The dosage could be increased up to 0.6mg/kg/dose depending
upon the subject’s clinical response and tolerability. The total dose
could be administered in two or three doses/day. The duration of the
renewable prescription was 1 month.
Group B. This group consisted of subjects treated with ATX
plus behavioral treatment. Atomoxetine chlorhydrate (5mg, 10mg,
18mg, 25mg, 40mg, or 60mg tablets; Strattera, Lilly) was used.
Route of administration was oral, with the following schedule:
Beginning with 0.5mg/kg/day once a day, at least for 7 days, then
increase the dose up 1.2mg/kg/day, related to the subject’s clinical
response and tolerability. Duration of the renewable prescription
was 1 month.
Data collection and management
All relevant information was collected by standard procedures.
The clinical assessment was performed monthly, and included
measurement of height in centimeters, and of weight in kilograms.
Height and weight measurements were collected in according
Tanner’s standard procedure (Tanner et al. 1966). Each measure of
weight and height was also computed in percentiles.
Clinical monitoring of the register included regular checking via
the Internet. All clinical data, relative to recruitment and follow-up of
each enrolled child, were entered in an electronic Case Report Form
(eCRF), that was located in a restricted area (https://www.farmaco
-iss.org/cgi-bin/adhd/index_gen) of the web site www.iss.it/adhd.
Centers, child psychiatrist services, and pediatricians could access
this restricted area through user i.d. and password.
The database of the register was based at Istituto Superiore di
Sanita`, Rome, which was responsible for its protection and man-
agement. The data management was designed by an infrastructure
named ‘‘Advanced Multicenter Research developed by Consorzio
Inter-Universitario per il Calcolo Automatico dell’Italia nord-
orientale.’’ This program application allowed the checking of any
informative flow, the data input, the monitoring of information, and
the analysis of results.
Determination of sample size
The required sample size was estimated with respect to the 1
year variation in height z-score (the primary outcome of the study),
based on the paired Student’s t test (comparison of the mean value
between baseline and 12 months within the treatment group), two
tailed (we were interested in demonstrating differences in height z-
score variation in whatever direction).
From previous studies, the standard deviation of the 1 year
variation in height z-score in the overall group of subjects, apart
from sex and age, was estimated at 0.4.
Moreover, we considered as clinically relevant a z-score dif-
ference from baseline to 12 months height z-score variation ‡ 0.1
(corresponding to a Cohen’s d= 0.25, i.e., a small-to-medium effect
size according to Cohen, 1988). Finally, considering a type I error
probability a= 0.05 and a power 1-b = 0.80, the minimal sample
size required for the study was 133 subjects in each treatment
group.
This sample size also allowed for detection of a difference be-
tween MPH and ATX groups in the height z-score 1 year variation
‡ 0.15 (corresponding to a Cohen’s d = 0.375, i.e., a small-to-
medium effect size according to Cohen, 1988), based on a two
tailed Student’s t test for independent samples, with a type I error
probability a= 0.05 and a power 1-b= 0.85.
Statistical analysis
Categorical variables (i.e., sex, treatment, and height and weight
percentile changes) are shown as absolute and percent frequencies,
whereas quantitative variables (age, height, weight) are summa-
rized as means – standard deviations.
In order to maximize the number of subjects included in the
statistical analyses, data were separately analyzed according to
three reference periods: From enrollment (time 0) to 6 months, from
0 to 12 months, and from 0 to 24 months of follow-up. With respect
to treatment, subjects were divided into four groups according to
drug(s) received during the reference period under examination:
MPH-treated (MPH group), ATX-treated (ATX group), both
drugs-treated (MIXED group), and those not treated with either
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MPH or ATX, but receiving other psychotropic drugs. The last two
groups were excluded from the analysis (Fig. 1).
For any reference period, only subjects with data at baseline and
at the end of the period were included in the statistical analyses.
To assess the difference between observed and expected changes
in height and weight during each reference periods, heights and
weights were categorized in percentile classes (from 0 to 3rd,
from >3rd to 10th, from >10th to 25th, from >25th to 50th,
from >50th to 75th, from >75th to 90th, from >90th to 97th, and
>97th percentile) based on Tanner’s age- and sex-specific data.
Subsequently, each subject was classified as passing to a lower
percentile (percentile decreased), remaining in the same percentile
(percentile unchanged), or passing to a higher percentile (percentile
increased) from baseline to the end of the reference period. The
frequency of subjects shifting to a lower percentile class was
compared with that of those moving to a higher class using the
binomial test. Moreover, the distribution of subjects according to
the percentile variation from baseline to the end of the period was
compared between the two treatment groups, using the v2 test.
To take into account the effect of sex and age, height was also
transformed in z-score, according to the formula
height z-score¼ (heightiheight mean)
= height standard deviations
where heighti = height of the subject at the time of assessment,
height mean =mean of sex- and age-specific height, height standard
deviation = standard deviation of sex- and age-specific height, us-
ing sex- and age-specific height means and standard deviations
taken from Tanner’s tables on cross-sectional-type standards for
height attained (Tanner et al. 1966).
Because of asymmetry in the variable distribution, weight could
not be transformed in z-scores, and, therefore, was analyzed and
presented as raw data.
Comparisons within the MPH or ATX groups with respect to
height and weight data were performed by paired Student’s t test to
compare measurements taken at baseline and at the end of the
specific reference period within each treatment group. The differ-
ences between the MPH and ATX groups for height and weight
changes, occurring during the period, were tested using Student’s t
test for independent samples. Nonparametric tests (Wilcoxon and
Mann–Whitney U tests for paired data and independent samples,
respectively) were also performed on weight data to validate results
of parametric tests. As the results were concordant, only parametric
tests were reported.
Results
Through June 30 2010, 1758 children and adolescents with
ADHD were recruited from the Italian ADHD National Registry.
Of these, 1558 (88.6%) were males. Analyzing age classes, sub-
jects <11 years were the most represented (991 subjects) and ac-
counted for*57% of the entire population.
Stratified by type of treatment, 840 (47.8%) subjects were
treated with MPH and 918 (52.2%) were treated with ATX.
FIG. 1. Flow chart of patients at 6 months of follow-up. The figure reports the number of patients included in weight and height
analysis, stratified for each group of treatment (methylphenidate group, atomoxetine group). The reasons for which the patients were
excluded from analysis were also reported.
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MPH was prescribed at average daily dose equal to 0.48mg/kg
(SD – 0.22) and with total average daily dose of 18.8mg
(SD – 10.7). ATX was prescribed at average daily dose of 38.7mg
(SD – 20.5).
Subjects in the MPH or ATX groups in relation to the three
different periods (0 vs. 6 months, 0 vs. 12 months, 0 vs. 24 months)
were compared with respect to age at baseline and sex distribution.
No significant differences were found between MPH and ATX
groups, except for sex when comparing the two groups of treatment
in relation to the period 0 versus 24 months, when a lower pro-
portion of females was observed in the ATX group (46 males and
9 females in the MPH group vs. 34 males and only 1 female in the
ATX group, p= 0.047).
During the study, monitoring of height and weight was re-
commended monthly. The mean number of height measures per
subject was 6.11, ranging from 1 to 33, whereas the mean number
of weight measures per subject was 6.14, ranging from 1 to 33.
For primary analysis, we used follow-up data at 6, 12, and 24
months. One thousand and sixty-four (60.5%) subjects dropped out
of the study. Reasons for dropping out are reported in Figure 1.
Weight evaluation
Five hundred and ninety subjects were included in the analysis
(Table 1). The comparison for age, sex, subtype of ADHD and
comorbidity showed no significant differences between the subjects
included in the analysis and those excluded, except for the de-
pression. Two hundred and ninety-six out of 590 (50.2%) were
treated with MPH and 294 (49.8%) were treated with Atomoxetine.
Percentile variations are shown in Table 2. As can be seen, in all
reference periods, the proportion of subjects shifting to a lower per-
centile class was larger than that of those moving to a higher per-
centile class. The difference between these two groups has always
been significant, except for MPH subjects in the reference period 0–
24months. The differencewas stronger inATX- than inMPH-treated
Table 1. Demographic and Clinical Characteristics
of Subjects Stratified by groups Included and not
Included in the Weight Analysis
Variables
Included in the
analysis 590
subjects
Not included in
the analysis
1168 subjects
Gender, n (%)
Male 514 (87.1) 1044 (89.4)
Female 76 (12.9) 124 (10.6)
Age class, n (%)
<11 years 341 (57.8) 662 (56.8)
11 - <15 years 207 (35.1) 406 (34.9)
‡15 years 42 (7.1) 97 (8.3)
Type of ADHD, n (%)
ADHD – I 33 (5.6) 61 (5.2)
ADHD – H 26 (4.4) 60 (5.1)
ADHD – C 531 (90.0) 1028 (88.0)
Presence of comorbidity
Oppositional defiant disorder 247 (41.9) 463 (39.6)
Conduct disorder 32 (5.4) 79 (6.8)
Depression 32 (5.4) 82 (7.0)
Anxiety 73 (12.4) 190 (16.3)
Learning disorder 269 (45.6) 479 (41.0)
ADHD, attention-deficit/hyperactivity disorder; ADHD-I, Subtype
Inattentive ADHD; ADHD-H, Subtype Hyperactive ADHD; ADHD-C,
Subtype Combined ADHD.
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subjects; however, the difference between the two groups was sig-
nificant only for the reference periods 0–6 months and 0–12 months.
We calculated the mean value of weight before the treatment and
after 6, 12, and 24 months. For MPH, at each time point, a statis-
tically significant weight increase was detected. The mean differ-
ence from baseline was + 1.21 (SD 2.66) kg at 6 months, + 3.21
(SD 3.63) kg at 1 year, and + 8.44 (SD 5.18) kg at 24 months
( p < 0.001 for all periods). Similarly, a statistically significant
difference was observed for ATX. The mean difference from
baseline was + 0.38 (SD 3.03) kg at 6 months, + 2.03 (SD 4.11) kg
at 1 year, and + 5.65 (SD 5.44) kg at 24 months ( p = 0.031,
p < 0.001, and p< 0.001, respectively). These findings are sum-
marized in Table 3. The comparison between MPH- and ATX-
treated patients with respect to weight change at 6, 12, and 24
months shows a statistically significant difference ( p< 0.001,
p = 0.005 and p= 0.025, respectively).
Height evaluation
Five hundred and seventy-four subjects were included in the
analyses (Table 4). The comparison for age, sex, subtype of ADHD,
and comorbidity between the group included in the analysis and the
one excluded, showed a statistically significant difference only for
anxiety. Two hundred and eighty-eight out of 574 (50.2%) were
treated with MPH and 286 (49.8%) were treated with ATX.
Percentile variations are shown in Table 5. The proportion of
subjects shifting to a lower percentile class was higher than that of
those moving to a higher percentile class, but the difference was
significant only for ATX subjects in the reference periods 0–12
months and 0–24 months. The difference was slightly stronger in
ATX- than in MPH-treated subjects; however, the difference be-
tween the two groups never reached statistical significance.
We analyzed the mean value of height before the treatment and
after 6, 12, and 24 months (Table 6). A statistically significant
increase of height was detected in the MPH group. The mean dif-
ference from baseline was +2.92 (SD 2.32) cm at 6 months, +5.01
(SD 2.77) cm at 1 year, and +10.48 (SD 4.83) cm at 24 months
( p<0.001 for all periods). For ATX, the difference from baseline
was +2. 64 (SD 2.50) cm at 6 months, +4.09 (SD 2.80) cm at 1
year, and +8.31 (SD 5.31) cm at 24 months ( p < 0.001 for all
periods). At any period, height increase in the ATX group was
lower than the corresponding increase observed in the MPH group,
but the difference was significant only after ‡ 1 year of treatment
( p= 0.176, p = 0.004, and p= 0.050 for 6, 12, and 24 months,
respectively).
Z-score for height
When considering height z-scores, the mean difference from
baseline forMPHwas - 0.001 (SD 0.334) at 6 months, - 0.104 (SD
0.381) at 12 months, and - 0.175 (SD 0.660) at 24 months
( p= 0.961, p< 0.001, and p = 0.055 for 6, 12, and 24 months, re-
spectively). For ATX, the difference from baseline was - 0.037
Table 3. Weight of Patients Stratified by Type of Drugs at Different Times from Enrolment
MPH
n
Mean – SD
(kg)
ATX
n
Mean – SD
(kg)
MPH vs ATX
t testa
0 months 296 38.70– 13.40 294 41.03– 15.84
6 months 39.91– 13.75 41.41– 15.76
0 vs 6 mo. t testb t295= 7.85 t293= 2.17 t588 = 3.53
p < 0.001 p < 0.031 p< 0.001
0 months 184 38.38– 13.26 159 40.55– 13.93
12 months 41.58– 13.72 42.58– 14.42
0 vs 12 mo. t testb t183 = 11.98 t158= 6.23 t341 = 2.81
p < 0.001 p < 0.001 p< 0.005
0 months 55 38.36– 11.31 28 43.46– 17.35
24 months 46.80– 13.41 49.11– 18.33
0 vs 24 mo. t testb t54 = 12.08 t27 = 5.48 t81 = 2.28
p < 0.001 p < 0.001 p< 0.025
Weights are reported as means– standard deviations in kg.
aUnpaired Student’s t test: Comparisons between MPH- and ATX-treated subjects regarding weight changes between baseline and the end of the
specific reference period.
bPaired Student’s t test: Comparisons between measurements taken at baseline and at the end of the specific reference period, within each treatment group.
MPH, methylphenidate; ATX, atomoxetine; df, degrees of freedom.
Table 4. Demographic and Clinical Characteristics
of Subjects Stratified by Groups Included
and not Included in the Height Analysis
Variables
Included in the
analysis 574
subjects
Not included in
the analysis
1184 subjects
Gender, n (%)
Male 500 (87.1) 1058 (89.3)
Female 74 (12.9) 126 (10.7)
Age class, n (%)
<11 years 340 (59.3) 663 (56.0)
11 to <15 years 200 (34.8) 413 (35.0)
‡15 years 34 (5.9) 105 (9.0)
Type of ADHD, n (%)
ADHD – I 33 (5.7) 61 (5.1)
ADHD – H 27 (4.7) 59 (4.9)
ADHD – C 514 (89.6) 1045 (90.0)
Presence of comorbidity
Oppositional defiant disorder 243 (42.3) 467 (39.4)
Conduct disorder 33 (5.7) 78 (6.6)
Depression 33 (5.7) 81 (6.8)
Anxiety 69 (12.0) 194 (16.4)
Learning disorder 265 (46.2) 483 (40.1)
ADHD, attention-deficit/hyperactivity disorder; ADHD-I, Subtype
Inattentive ADHD; ADHD-H, Subtype Hyperactive ADHD; ADHD-C,
Subtype Combined ADHD.
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(SD 0.375) at 6 months, - 0.229 (SD 0.399) at 12 months, and
- 0.441 (SD 0.734) at 24 months ( p = 0.093, p < 0.001, p = 0.001
for 6, 12, and 24 months, respectively). At any period, height z-
score decrease in the ATX group was higher than the corresponding
decrease observed in the MPH group, but the difference was sig-
nificant only at 1 year of treatment ( p= 0.220, p= 0.006, and
p= 0.203 for 6, 12, and 24 months, respectively). The results are
summarized in Table 7.
Discussion
This observational study assessed the impact of MPH and ATX
on growth. The study showed a different growth rate between the
two drugs, with ATX-treated patients growing significantly more
slowly than MPH-treated patients.
With regard to weight, there was a significant trend for weight
increase for both drugs. For the effect on height we observed a
statistically significant decrease, evaluated in percentiles, for both
drugs. However, comparing the effect between the two drugs on
height decrease, a statistically significant difference were observed
only at 12 months.
Although the two variables, weight and height, are both im-
portant in the assessment of growth, height is more important be-
cause, once growth stops at the end of adolescence, height cannot
increase any more, whereas weight changes throughout life.
Therefore, in order to more accurately assess growth with re-
spect to height, we used the z-score that correlates with chrono-
logical age and gender.
The z-score values after 12 and 24 months of therapy were more
reduced in the ATX group than in the MPH one, but a significant
difference was detected only at 12 months. At 24 months of follow-
up, a greater difference in z-score between the two groups was ob-
served, but it is not statistically significant, because the number of
subjects included in this subanalysis, in the two groups, was lower.
Therefore, it is possible to state that, in the first year of treatment,
ATX causes a significantly greater growth delay than MPH. Ad-
ditionally, both drugs showed a cumulative effect over time. After 24
months, the z-score had halved for both groups. Our results are in
accordance with other studies (Spencer et al. 2005; Charach et al.
2006), in which a slowdown of growth rate in long-term treated
patients was observed. Although this finding is also confirmed by a
recent review (Faraone 2008), a recent naturalistic study did not
support any association between deficits in growth process and
psychostimulant treatment in ADHD patients (Villarreal et al. 2010).
As for ATX, a meta-analysis of long-term studies of ATX in
children showed that the stronger negative effect occurred after 18
months of treatment, and that then this effect decreased with time
(Spencer et al. 2005). A recent randomized, double-blind, placebo-
controlled study of a Japanese pediatric population showed that the
mean height increases in the ATX group were lower than those in
the placebo group (Takahashi et al. 2009). On the other hand, one
placebo-controlled trial did not show clinically significant effects
on growth rate with ATX (Donnelly et al. 2009).
Our results should be considered in the light of study limitations.
First, it is not clear whether the observed slowdown in growth is a
transient effect or a permanent potential reduction for individual
growth with respect to the final height. As our observation time was
only 24 months of follow-up, we were not able to evaluate if the
negative effect on growth persisted after 24 months of treatment.
Second, we could not assess if the negative effect observed on height
would persist after permanent discontinuation of drugs (Safer et al.
1975). Unfortunately, our study did not include a specific follow-up
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for subjects with permanent discontinuation of treatment. Third,
*60% of subjects could not be included in the statistical analyses.
To understand the relative impact of this issue on the results, we
compared ‘‘population included’’ versus ‘‘population not included’’
in the statistical analysis, following some factors, such as age classes,
sex, subtype of ADHD, and comorbidity. Statistically significant
differences were observed only for depression in the weight analysis
and for anxiety in the height analysis. Therefore, we believe that the
population included in the analysis was representative of the whole
population enrolled in the Italian ADHD National Registry.
Conclusions
The long-term effects of therapies for chronic diseases represent
one of the most important issues in the evaluation of the profile
benefit/risk. Our study highlights that the use of MPH and ATX in
children and adolescents with ADHD seems not to be the cause of
permanent growth effects. Both drugs cause a moderate slowdown
in the height velocity highlighted by the values of the z-score.
However, this effect does not seem to be permanent, and there is no
significant difference between ATX and MPH. On the other hand,
both drugs cause an increase in the average weight in pharmacolog-
ically treated patients. After 2 years of pharmacological treatment, we
have observed an average weight about +5 SD from the 50th per-
centile. This finding should be confirmed by a randomized controlled
study with two active drug arms and one control group.
Clinical Significance
Regular monitoring of growth parameters (parent’s height,
height, and weight measurements) is recommended for all patients,
but it should be strongly recommended for subjects treated with
ADHD drugs. So far, attention has been focused on the effect of
ADHD medications on height growth. In view of our findings, it is
necessary to devote the same attention to the risk of onset of obesity
in patients treated with these drugs.
Table 6. Height of Patients Stratified by Type of Drugs at Different Times from Enrolment
MPH
n
Mean – SD
(cm)
ATX
n
Mean – SD
(cm)
MPH vs ATX
t testa
0 months 288 140.90– 15.12 286 143.02– 17.01
6 months 143.82– 15.22 145.66– 17.04
0 vs 6 mo. t testb t287 = 21.36 t285 = 17.87 t572 = 1.36
p< 0.001 p< 0.001 p= 0.176
0 months 167 141.22– 15.50 139 144.01– 16.89
12 months 146.23– 15.73 148.10– 17.00
0 vs 12 mo. t testb t166 = 23.34 t138 = 17.25 t304 = 2.87
p< 0.001 p< 0.001 p= 0.004
0 months 55 140.45– 14.49 35 145.49– 17.57
24 months 150.93– 15.04 153.80– 18.18
0 vs 24 mo. t testb t54 = 16.08 t34 = 9.26 t88 = 1.99
p< 0.001 p< 0.001 p= 0.050
Heights are reported as means– standard deviations in cm.
aUnpaired Student’s t test: Comparisons between MPH and ATX-treated subjects regarding weight changes between baseline and the end of the
specific reference period.
bPaired Student’s t test: Comparisons between measurements taken at baseline and at the end of the specific reference period, within each treatment
group.
MPH, methylphenidate; ATX, atomoxetine; df, degrees of freedom.
Table 7. Height z-Scores of Patients Stratified by Type of Drugs at Different Times from Enrolment
MPH
n Mean – SD
ATX
n Mean – SD
MPH vs ATX
t testa
0 months 288 0.35 – 1.19 286 0.32 – 1.27
6 months 0.35 – 1.16 0.27 – 1.20
0 vs 6 mo. t testb t287 = 0.05 t285 = 1.68 t572 = 1.23
p< 0.961 p < 0.093 p= 0.220
0 months 167 0.37 – 1.22 139 0.55 – 1.21
12 months 0.27 – 1.19 0.32 – 1.16
0 vs 12 mo. t testb t166 = 3.54 t138 = 6.77 t304 = 2.79
p< 0.001 p < 0.001 p= 0.006
0 months 55 0.36 – 1.21 35 0.84 – 1.22
24 months 0.18 – 1.12 0.40 – 1.30
0 vs 24 mo. t testb t54 = 1.96 t34 = 3.55 t88 = 1.27
p< 0.055 p < 0.001 p= 0.203
aUnpaired Student’s t test: Comparisons between MPH and ATX-treated subjects regarding weight changes between baseline and the end of the
specific reference period.
bPaired Student’s t test: Comparisons between measurements taken at baseline and at the end of the specific reference period, within each treatment
group.
MPH, methylphenidate; ATX, atomoxetine; df, degrees of freedom.
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